Capricor Therapeutics (CAPR)
Develops deramiocel for Duchenne muscular dystrophy and StealthX exosome therapies.
Something off on this page? Send us feedback.
Develops cell and exosome-based therapies, led by deramiocel for Duchenne muscular dystrophy and the StealthX platform. Product sales are still pre-commercial; the business depends on FDA review, manufacturing execution, and Nippon Shinyaku distribution arrangements in the United States and Japan.
Develops deramiocel, an allogeneic cell therapy made from cardiosphere-derived cells, for Duchenne muscular dystrophy. The broader pipeline includes StealthX, an engineered-exosome platform for vaccines and therapeutic delivery.
Execution centers on clinical development, regulatory approval work, and manufacturing responsibility from a San Diego base, with one reportable segment focused on therapeutic-candidate development and commercialization. The strategy reflects a pivot from earlier heart-disease programs toward DMD and exosome research.
Product sales have not begun because deramiocel and StealthX remain investigational. Regulatory review, manufacturing responsibility, and the Nippon Shinyaku distribution arrangements for the United States and Japan shape the near-term business structure.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 14, 2026 | B. Riley | Upgrade | ||
| Sep 14, 2026 | B.Riley Financial | Target | Target: — | Target: $21 |
| Sep 14, 2026 | B. Riley Securities | Upgrade | ||
| Sep 1, 2026 | Piper Sandler | Upgrade | Target: $45 | Target: $25 |
| Aug 25, 2026 | Oppenheimer | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $237.9M · Total debt $91.0M · Total assets $368.7M · Shareholders' equity $246.2M
- Revenue
- $0
- Operating income
- −$42.9M
- Net income
- −$40.7M
No dividends on record.
| Institutions | ≈ 67.46% | 39.22M shares | |
|---|---|---|---|
| 196 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.87% | 504.8K shares | |
| 6 holders · as of Jun 29, 2026 | |||
| Strategic holders | 12.20% | 7.09M shares | |
| 1 holder · as of Sep 24, 2024 | |||
| Other | ≈ 19.47% | 11.32M shares | |
| remainder | |||
58.14M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Nippon Shinyaku Co LtdStrategic10 percent owner | 12.20% | 7.09M | filed Sep 24, 2024 |
BlackRock, Inc.Institution | 7.13% | 4.15M | as of Jun 30, 2026 |
Tang Capital Management LLCInstitution | 7.05% | 4.10M | as of Jun 30, 2026 |
Suvretta Capital Management, LLCInstitution | 7.04% | 4.09M | as of Jun 30, 2026 |
State Street CorpInstitution | 5.84% | 3.40M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 25, 2026 | Anthony Bergmann | officer: CHIEF FINANCIAL OFFICER | −24,100 | $30.38 |
| Jun 25, 2026 | Karen Krasney | officer: EVP, GENERAL COUNSEL | −24,100 | $30.38 |
| Jun 24, 2026 | Anthony Bergmann | officer: CHIEF FINANCIAL OFFICER | −400 | $30.00 |
| Jun 24, 2026 | Karen Krasney | officer: EVP, GENERAL COUNSEL | −400 | $30.00 |
| May 1, 2026 | Anthony Bergmann | officer: CHIEF FINANCIAL OFFICER | −25,000 | $31.70 |
- Sarepta Therapeutics
Dominant approved DMD portfolio across exon skipping and gene therapy
- Dyne Therapeutics
Late-stage exon 51 DMD RNA therapy challenger
- REGENXBIO
Late-stage microdystrophin gene-therapy competitor
- Solid Biosciences
Phase 3 Duchenne gene therapy with cardiac-muscle emphasis
- Novartis (ADR)
Avidity-derived DMD44 RNA program inside a traded ADR
- Edgewise Therapeutics
Transitional sevasemten owner in DMD muscle protection
- PTC Therapeutics
Commercial DMD drugs with narrower current overlap
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Capricor Therapeutics | $8.60 | −7.97% | $537.1M | — | — | — | — |
| Sarepta Therapeutics | $19.20 | −7.74% | $2.20B | — | 33.4 | 1.1 | −34.3% |
| Dyne Therapeutics | $16.36 | −4.57% | $3.20B | — | — | — | — |
| REGENXBIO | $7.49 | −8.06% | $421.3M | — | — | 2.4 | +405.7% |
| Solid Biosciences | $8.03 | −9.99% | $878.2M | — | — | — | — |
| Novartis (ADR) | $142.36 | +0.76% | $268.53B | 21.3 | 15.1 | 4.8 | +0.9% |
| Edgewise Therapeutics | $40.38 | −9.28% | $4.79B | — | — | — | — |
| PTC Therapeutics | $63.05 | −4.41% | $5.51B | — | 51.0 | 5.5 | +101.6% |
| Median | 21.3 | 33.4 | 3.6 | +51.2% |